Trial reportEuropean journal of heart failure2021
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.
Trial report in European journal of heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT03036124. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Open the trial in the graphWho cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Pooled it
- Sodium-glucose cotransporter-2 inhibitors in heart failure patients across the range of body mass index: a systematic review and meta-analysis of randomized controlled trials.Internal and emergency medicine · 2024Pooled it
- Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced.European journal of heart failure · 2023Trial
- Revisiting the obesity paradox in patients with heart failure with reduced ejection fraction in the light of contemporary guideline-directed medical therapy.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Frailty in Patients with Heart Failure.Internal medicine (Tokyo, Japan) · 2026Article
- Obesity and Heart Failure: Introducing the Theme.Journal of cardiovascular development and disease · 2026Review
- Sodium-Glucose Cotransporter 2 Inhibitors in Underweight Patients with Heart Failure: A Case Series.Journal of clinical medicine · 2026Article
- Real-world data on early initiation of sodium-glucose co-transporter-2 inhibitors in newly diagnosed heart failure with reduced ejection fraction.ESC heart failure · 2026Article
- Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?European heart journal · 2026Review
- Obesity and heart failure: exploring the cardiometabolic axis.Cardiovascular research · 2025Review
- Heart failure and obesity: Translational approaches and therapeutic perspectives. A scientific statement of the Heart Failure Association of the ESC.European journal of heart failure · 2025Article
- Refining the link between obesity and heart failure: insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures.Cardiovascular diabetology · 2025Review
- Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors for Patients With Heart Failure and Low Body Mass Index.Circulation reports · 2025Article
- Cachectic biomarkers as confounders behind the obesity paradox in patients with acute decompensated heart failure.International journal of obesity (2005) · 2025Article
- Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator.ESC heart failure · 2025Article
- Treatment options for heart failure in individuals with overweight or obesity: a review.Future cardiology · 2025Review
- Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study.European heart journal. Cardiovascular pharmacotherapy · 2025Article
- The Impact of Obesity on Cardiovascular Diseases: Heart Failure.Methodist DeBakey cardiovascular journal · 2025Review
- Preclinical modeling of metabolic syndrome to study the pleiotropic effects of novel antidiabetic therapy independent of obesity.Scientific reports · 2024Article
- Putting More Weight on Obesity Trials in Heart Failure.Current heart failure reports · 2024Review
Corrections and comments
- Commented on by
Authors and funding
24 authors at 17 institutions in 13 countries.
Funding
Abstract
aimsIn heart failure with reduced ejection fraction (HFrEF), there is an 'obesity paradox', where survival is better in patients with a higher body mass index (BMI) and weight loss is associated with worse outcomes. We examined the effect of a sodium-glucose co-transporter 2 inhibitor according to baseline BMI in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF). METHODS AND
resultsBody mass index was examined using standard categories, i.e. underweight (<18.5 kg/m
conclusionWe confirmed an 'obesity survival paradox' in HFrEF. We showed that dapagliflozin was beneficial across the wide range of BMI studied. CLINICAL
trial registrationClinicalTrials.gov NCT03036124.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.